ACTICOR BIOTECH: Topline Results of ACTISAVE Phase 2/3 Study in Stroke Treatment

PARIS--(BUSINESS WIRE)--Regulatory News: ACTICOR BIOTECH (FR0014005OJ5 - ALACT) (Paris:ALACT), a clinical-stage biotechnology company focused on the development of glenzocimab, an innovative drug for the treatment of cardiovascular emergencies, today announced the first results of its ACTISAVE phase 2/3 study in the treatment of acute ischemic stroke. Analysis of the first results shows no evidence of efficacy for either the primary endpoint, the proportion of patients with severe disability or